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INTRODUCTION
The American College of Cardiology (ACC)/American
Heart Association (AHA) guidelines for the management
of unstable angina and non–ST-segment elevation myocar-
dial infarction (UA/NSTEMI) were published in Septem-
ber 2000 (1). Since then, a number of clinical trials and
observational studies have been published or presented that,
when taken together, alter significantly the recommenda-
tions made in that document. Therefore, the ACC/AHA
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Committee on the Management of Patients With Unstable
Angina, with the concurrence of the ACC/AHA Task
Force on Practice Guidelines, revised these guidelines.
These revisions were prepared in December 2001, reviewed
and approved, and then published on the ACC World
Wide Web site (www.acc.org) and AHA World Wide Web
site (www.americanheart.org) on March 15, 2002. The
present article describes these revisions and provides further
updates in this rapidly moving field. Minor clarifications in
the wording of three recommendations that now appear
differently from those that were previously published on the
ACC and AHA Web sites are noted in footnotes.
The ACC/AHA classifications I, II, and III are used to
summarize indications as follows:
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or
treatment is useful and effective.
Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about the
usefulness/efficacy of a procedure or treatment.
IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
IIb: Usefulness/efficacy is less well established
by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treat-
ment is not useful/effective and in some cases
may be harmful.
The weight of the evidence was ranked highest (A) if the
data were derived from multiple randomized clinical trials
that involved large numbers of patients and intermediate (B)
if the data were derived from a limited number of random-
ized trials that involved small numbers of patients or from
careful analyses of nonrandomized studies or observational
registries. A lower rank (C) was given when expert consen-
sus was the primary basis for the recommendation.
RISK ASSESSMENT
Clinical Features
Unstable angina and NSTEMI are heterogeneous disorders
in which patients have widely varying risks. Risk is an
important “driver” of management decisions, and accurate
yet simple methods of risk assessment are important for
patient care.
Risk was assessed by multivariable regression techniques
in patients presenting with UA/NSTEMI in several large
clinical trials. Boersma et al. analyzed the relation between
baseline characteristics and the incidence of death and the
composite of death or myocardial (re)infarction at 30 days in
patients who entered the PURSUIT (Platelet IIb/IIIa in
Unstable angina: Receptor Suppression Using Integrilin
Therapy) trial (2). The most important baseline features
associated with death were age, heart rate, systolic blood
pressure, ST-segment depression, signs of heart failure, and
elevation of cardiac biomarkers. From this analysis, a simple
risk estimation score was developed.
Antman et al. developed a 7-point risk score, the “TIMI
Risk Score,” (age greater than or equal to 65 years, more
than 3 coronary risk factors, prior angiographic coronary
obstruction, ST-segment deviation, more than 2 angina
events within 24 h, use of aspirin [ASA] within 7 days, and
elevated cardiac markers) (3). The score was defined as the
simple sum of these individual prognostic variables. The risk
of developing an adverse outcome—death, (re)infarction, or
recurrent severe ischemia that required revascularization—
ranged from 5% with a score of 0 or 1 to 41% with a score
of 6 or 7. The score was derived from data in the TIMI 11B
(Thrombolysis In Myocardial Infarction 11B) trial (4) and
then validated in 3 additional trials—ESSENCE (Efficacy
and Safety of Subcutaneous Enoxaparin in Non–Q-wave
Coronary Events study) (5), and PRISM-PLUS (Platelet
Receptor inhibition for Ischemic Syndrome Management in
Patients Limited by Unstable Signs and symptoms) (6) and
prospectively in one TACTICS-TIMI 18 (Treat angina
with Aggrastat and determine Cost of Therapy with an
Invasive or Conservative Strategy–Thrombolysis In Myo-
cardial Infarction) 18 (7). A progressively greater benefit
from newer therapies such as low-molecular-weight heparin
(LMWH) (4,5), platelet glycoprotein (GP) IIb/IIIa recep-
tor antagonists (6), and an invasive strategy (7) with
increasing risk score have been reported.
Biomarkers
The Joint European Society of Cardiology/American Col-
lege of Cardiology Committee for the Redefinition of
Myocardial Infarction (8) emphasized the use of troponins
as critical markers of the presence of myocardial necrosis.
Although troponins are accurate in identifying myocardial
necrosis, the latter is not always secondary to atherosclerotic
coronary artery disease. Therefore, in establishing the diag-
nosis of NSTEMI, cardiac troponins should be used in
conjunction with appropriate clinical features and electro-
cardiographic changes. Myocardial injury of diverse origins
(e.g., myocarditis, trauma, or cardioversion) may cause
necrosis and release of troponins. Although these may be
considered instances of NSTEMI, they should be distin-
guished on clinical grounds from the more common form of
NSTEMI secondary to coronary atherosclerosis.
Antiplatelet Therapy
Antiplatelet therapy is a cornerstone in the management of
UA/NSTEMI. Three classes of antiplatelet drugs (ASA,
thienopyridines, and GP IIb/IIIa antagonists) have been
found useful in the management of these patients and are
the subject of continued intensive investigation and analysis.
Clopidogrel. Given its more rapid onset of action (9,10)
and better safety profile compared with ticlopidine, clopi-
dogrel is now the preferred thienopyridine. The CURE
(Clopidogrel in Unstable angina to prevent Recurrent isch-
emic Events) trial (11) randomized 12,562 patients with
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UA/STEMI who presented within 24 h to placebo or
clopidogrel (loading dose of 300 mg followed by 75 mg
daily) and followed them for 3 to 12 months; all patients
were given aspirin. Cardiovascular death, myocardial infarc-
tion (MI), or stroke occurred in 11.5% of patients assigned
to placebo and 9.3% of those assigned to clopidogrel
(relative risk [RR] 0.80; p less than 0.001). Looking at the
individual components of the primary composite and end
point, there was a trend in favor of clopidogrel for cardio-
vascular death and stroke (5.5% and 1.4%, respectively, for
placebo vs. 5.1% and 1.2% for clopidogrel), and there was a
significant reduction in MI (6.7% vs. 5.2% R.R.  0.77, p
less than 0.001). However, there was no significant differ-
ence in the incidence of non–Q-wave MI (3.8% vs. 3.5%).
A reduction in recurrent ischemia was noted within the first
few hours after randomization. These salutary results were
observed across all subgroups of patients. There was, how-
ever, a significant excess of major bleeding (2.7% in the
placebo group versus 3.7% in the clopidogrel group; p 
0.003) and of minor bleeding, as well as a (nonsignificant)
trend for an increase in life-threatening bleeding. The risk
of bleeding was increased in patients who underwent coro-
nary artery bypass grafting (CABG) within the first 5 days
after clopidogrel was discontinued.
The CURE trial was performed in hospitals in which
there was no routine policy of early invasive procedures, and
therefore, revascularization was performed during the initial
admission in only 23% of the patients, a substantially lower
percentage than currently receive this therapy at most US
hospitals. Although the addition of a GP IIb/IIIa antago-
nist appeared to be well tolerated in patients who were given
ASA, clopidogrel, and heparin in CURE, fewer than 10%
of patients received this combination. Therefore, additional
information on the safety of “quadruple therapy” (heparin
[unfractionated or low molecular weight], ASA, clopi-
dogrel, and a GP IIb/IIIa antagonist) should be obtained.
The CURE trial provides strong support for the addition
of clopidogrel to ASA on admission in the management of
patients with UA and NSTEMI. Clopidogrel appears to be
especially useful in hospitals that do not have a routine
policy of early invasive procedures and in patients who are
not candidates or who do not wish to be considered for
revascularization. The optimal duration of therapy with
clopidogrel has not been determined. The major benefits in
CURE were observed at 30 days, with small additional
benefits observed over the subsequent treatment period,
which averaged 8 months.
In PCI-CURE, a substudy of CURE, 2,658 patients who
underwent percutaneous coronary intervention (PCI) had
been randomly assigned to double-blind treatment with
clopidogrel (n  1,313) or placebo (n  1,345) (12); all
patients also received ASA. Patients were pretreated with
placebo or study drug for a median of 10 days before PCI.
After the procedure, most patients received open-label
thienopyridine (clopidogrel or ticlopidine) for approxi-
mately 4 weeks, after which the study drug (placebo or
clopidogrel) was again administered for an average of 8
months. The primary end point, a composite of cardiovas-
cular death, MI, or urgent target-vessel revascularization
within 30 days of PCI, occurred in 86 patients (6.4%) in the
placebo group compared with 59 (4.5%) in the clopidogrel
group (RR 0.70; p  0.03). When events that occurred
before and after PCI were considered, there was a 31%
reduction in cardiovascular death or MI with assignment to
clopidogrel (p  0.002). Thus, in patients with UA and
NSTEMI who are given ASA and are undergoing PCI, a
strategy of clopidogrel pretreatment followed by at least 1
month and probably longer-term therapy is beneficial in
reducing major cardiovascular events (12).
There now appears to be an important role for clopidogrel
in patients with UA/NSTEMI, both those who are man-
aged conservatively and those who undergo PCI, especially
stenting. However, it is not entirely clear how long therapy
should be maintained. Because clopidogrel, when added to
ASA, increases the risk of bleeding during major surgery in
patients who are scheduled for CABG, if possible, clopi-
dogrel should be withheld for at least 5 days (11) and
preferably for 7 days before surgery (13). In many hospitals
in which patients with UA/NSTEMI undergo diagnostic
catheterization within 24 to 36 h of admission, clopidogrel
is not started until it is clear that CABG will not be
scheduled within the next several days. A loading dose of
clopidogrel can be given to a patient on the catheterization
table if a PCI is to be performed immediately. If PCI is not
performed, clopidogrel can be begun after the catheteriza-
tion.
Glycoprotein IIb/IIIa antagonists in PCI. The introduc-
tion of platelet GP IIb/IIIa antagonists represents an
important advance in the treatment of patients with UA/
NSTEMI who are undergoing PCI. These drugs take
advantage of the fact that platelets play an important role in
the development of ischemic complications that may occur
in patients with UA/NSTEMI during coronary revascular-
ization procedures. The September 2000 guidelines empha-
sized the value of GP IIb/IIIa antagonists in patients with
UA/NSTEMI who were undergoing PCI (1).
Two trials of GP IIb/IIIa inhibitors have been published
since September 2000. The ESPRIT trial (Enhanced Sup-
pression of the Platelet IIb/IIIa Receptor with Integrilin
Therapy) was a placebo-controlled trial designed to assess
whether eptifibatide improved outcome in patients under-
going stenting (14). Fourteen percent of the 2,064 patients
enrolled in ESPRIT had UA/NSTEMI. The primary end
point (the composite of death, MI, target-vessel revascular-
ization, and “bailout” GP IIb/IIIa antagonist therapy) was
reduced from 10.5% to 6.6% with treatment (p  0.0015).
There was consistency in the reduction of events in all
components of the end point and in all major subgroups,
including patients with UA/NSTEMI. Major bleeding
occurred more frequently in patients who received eptifi-
batide (1.3%) than in those who received placebo (0.4%;
p  0.027); however, no significant difference in the
1368 Braunwald et al. JACC Vol. 40, No. 7, 2002
ACC/AHA Unstable Angina Guideline Update: Summary Article October 2, 2002:1366–74
transfusion rate occurred. At 1 year of follow-up, death or
MI occurred in 12.4% of patients assigned to placebo and
8.0% of eptifibatide-treated patients (hazard ratio 0.63; 95%
confidence interval [CI] 0.48 to 0.83; p  0.001) (15).
In the only head-to-head comparison of GP IIb/IIIa
antagonists, the TARGET trial (Do Tirofiban and ReoPro
Give similar Efficacy? Trial) randomized 5,308 patients to
tirofiban or abciximab before PCI with the intent to
perform stenting (16). The primary end point, a composite
of death, nonfatal MI, and urgent target-vessel revascular-
ization at 30 days, occurred less frequently in those given
abciximab than in those given tirofiban (6.0% vs. 7.6%; p 
0.038). There was a similar direction and magnitude for
each component of the end point. The difference in out-
come between the 2 treatment groups may be related to a
suboptimal dose of tirofiban resulting in inadequate platelet
inhibition. However, by six months, the primary end point
occurred in a similar percentage of patients in each group
(14.9% tirofiban vs. 14.3 % abciximab, NS). Mortality was
also similar (1.9% vs. 1.7%, NS) (17).
Glycoprotein IIb/IIIa antagonists without scheduled
PCI. The Global Utilization of Strategies to Open Oc-
cluded Coronary Arteries IV-Acute Coronary Syndromes
(GUSTO IV-ACS) trial (18) enrolled 7,800 patients with
UA/NSTEMI who were admitted to the hospital with
more than 5 min of chest pain and ST-segment depression
and/or elevated troponin T or I concentration and in whom
early (less than 48 h) revascularization was not intended to
be conducted. All received ASA and either unfractionated
heparin (UFH) or LMWH. They were randomized to
placebo, an abciximab bolus and 24-h infusion, or an
abciximab bolus and 48-h infusion. The primary end point,
death or MI at 30 days, occurred in 8.0% of patients given
placebo, 8.2% given 24-h abciximab, and 9.1% given 48-h
abciximab, differences that were not statistically significant.
At 48 h, death occurred in 0.3%, 0.7%, and 0.9% in these
groups, respectively (placebo vs. abciximab 48 h, p 0.008).
The lack of benefit of abciximab was observed in most
subgroups, including patients with elevated concentrations
of troponin who were at higher risk. Although the expla-
nation for these results is not clear, they indicate that
abciximab, at least at the dosing regimen used in GUSTO
IV-ACS, is not indicated in the management of patients
with UA or NSTEMI in whom an early invasive manage-
ment strategy is not planned.
In the PRISM-PLUS trial, 1,069 patients did not un-
dergo early PCI. Although tirofiban treatment was associ-
ated with a lower incidence of death, MI or death, and MI
or refractory ischemia at 30 days, these reductions were not
statistically significant (19). In a high-risk subgroup of these
patients not undergoing PCI (TIMI risk score greater than
or equal to 4) (3), tirofiban appeared to be beneficial
whether they underwent PCI (odds ratio [OR] 0.60, 95%
CI 0.35 to 1.01) or not (OR 0.69, 95% CI 0.49 to 0.99).
However, no benefit was observed in the patients at lower
risk (6). In the PURSUIT trial, eptifibatide reduced the
incidence of death or MI from 15.7% to 14.2% (RR 0.91;
95% CI 0.79 to 1.00; p  0.032) (20).
Boersma et al performed a meta-analysis of GP IIb/IIIa
antagonists in all 6 large, randomized, placebo-controlled
trials, including GUSTO IV-ACS (18), which involved
31,402 patients with UA/NSTEMI who were not routinely
scheduled to undergo coronary revascularization (21). A
small reduction in the odds of death or MI in the active
treatment arm (11.8% vs 10.8%; OR 0.91, 95% CI 0.84 to
0.98; p  0.015) was observed. Unexpectedly, no benefit
was observed in women (test for interaction between treat-
ment assignment and gender, p less than 0.0001). However,
women with positive troponins derived a treatment benefit
that was similar to men. In the meta-analysis, reductions in
the end points of death or nonfatal MI considered individ-
ually did not achieve statistical significance.
Although not scheduled for coronary revascularization
procedures, 11,965 of the 31,402 patients (38%) actually
underwent PCI or CABG within 30 days, and in this
subgroup, the OR for death or MI in patients assigned to
GP IIb/IIIa antagonists was 0.89 (95% CI 0.80 to 0.98). In
the other 19,416 patients who did not undergo coronary
revascularization, the OR for death or MI in the GP
IIb/IIIa group was 0.95 (95% CI 0.86 to 1.05, p  NS).
Major bleeding complications were increased in the GP
IIb/IIIa antagonist-treated group compared with those who
received placebo (1.4% vs. 2.4%, p less than 0.0001). The
authors concluded that in patients with UA/NSTEMI who
were not routinely scheduled for early revascularization and
who were at high risk of thrombotic complications, “treat-
ment with a GP IIb/IIIa inhibitor might therefore be
considered” (21). Thus, GP IIb/IIIa inhibitors are of benefit
in high-risk patients with UA/NSTEMI, and their admin-
istration, in addition to ASA and heparin, to patients in
whom catheterization and PCI are planned received a Class
I recommendation. These agents are of questionable benefit
in patients who do not undergo PCI. However, the revised
guidelines recommend broader indications for a routine
invasive strategy (see following text).
Thus, clopidogrel (in addition to aspirin and heparin or
low molecular weight heparin) is recommended for patients
with UA/NSTEMI in whom a noninterventional approach
is planned (Class I recommendation). In patients in whom
an interventional approach is planned, a GP IIb/IIIa inhib-
itor (in addition to aspirin and heparin or low molecular
weight heparin) is recommended (Class I recommendation).
No head-to-head comparison of clopidogrel, a GP IIb/IIIa
inhibitor, and their combination has been reported. The
addition of a GP IIb/IIIa inhibitor to a subset of patients in
the CURE trial who were receiving aspirin, clopidogrel, and
heparin appeared to be well tolerated, and current practice
frequently involves the use of this combination of drugs.
However, until further information on the safety and
efficacy of such quadruple therapy becomes available, a Class
IIa recommendation is made for the addition of a GP
IIb/IIIa inhibitor for patients with UA/NSTEMI who are
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receiving aspirin, clopidogrel, and unfractionated or low
molecular weight heparin and who are referred for an
invasive strategy. A Class I recommendation is made for a
GP IIb/IIIa inhibitor at the time of PCI in patients
receiving heparin and aspirin. Specific updated recommen-
dations for the use of antiplatelet regimens in the revised
guidelines are as follows:
Class I
1. Antiplatelet therapy should be initiated promptly.
ASA should be administered as soon as possible
after presentation and continued indefinitely.
(Level of Evidence: A)
2. Clopidogrel should be administered to hospital-
ized patients who are unable to take ASA because
of hypersensitivity or major gastrointestinal intol-
erance. (Level of Evidence: A)
*3. In hospitalized patients in whom an early nonin-
terventional approach is planned, clopidogrel
should be added to ASA as soon as possible on
admission and administered for at least 1 month
(Level of Evidence: A), and for up to 9 months.
(Level of Evidence: B)
*4. A platelet GP IIb/IIIa antagonist should be ad-
ministered, in addition to ASA and heparin, to
patients in whom catheterization and PCI are
planned. The GP IIb/IIIa antagonist may also be
administered just prior to PCI. (Level of Evidence:
A)
*†5. In patients for whom a PCI is planned and who are
not at high risk for bleeding, clopidogrel should be
started and continued for at least 1 month (Level of
Evidence: A) and for up to 9 months. (Level of
Evidence: B)
*6. In patients taking clopidogrel in whom elective
CABG is planned, the drug should be withheld for
5 to 7 days. (Level of Evidence: B)
Class IIa
*1. Eptifibatide or tirofiban should be administered, in
addition to ASA and LMWH or UFH, to patients
with continuing ischemia, an elevated troponin, or
with other high-risk features in whom an invasive
management strategy is not planned. (Level of
Evidence: A)
*2. A platelet GP IIb/IIIa antagonist should be ad-
ministered to patients already receiving heparin,
ASA, and clopidogrel in whom catheterization and
PCI are planned. The GP IIb/IIIa antagonist may
also be administered just prior to PCI. (Level of
Evidence: B)
Class IIb
*1. Eptifibatide or tirofiban, in addition to ASA and
LMWH or UFH, to patients without continuing
ischemia who have no other high-risk features and
in whom PCI is not planned. (Level of Evidence: A)
Class III
1. Intravenous fibrinolytic therapy in patients with-
out acute ST-segment elevation, a true posterior
MI, or a presumed new left bundle-branch block.
(Level of Evidence: A)
*2. Abciximab administration in patients in whom
PCI is not planned. (Level of Evidence: A)
*New indication, not included in the September 2000 guide-
lines.
†Minor clarification different from full-text version on web
site.
Anticoagulant Therapy
The September 2000 guidelines (1) reviewed the evidence
regarding the use of intravenous UFH or subcutaneous
LMWH. It provided the following Class I recommendation:
“Parenteral anticoagulation with intravenous UFH or
subcutaneous LMWH should be added to antiplatelet
therapy with ASA or a thienopyridine. (Level of Evi-
dence: B)”
In the interim, a number of studies have appeared that
support the use of enoxaparin. In the EVET trial (Enox-
aparin VErsus Tinzaparin in the management of unstable
coronary artery disease), 2 LMWHs, enoxaparin and tinza-
parin, administered for 7 days, were compared in 438
patients with UA/NSTEMI. A preliminary report stated
that both the recurrence of unstable angina and the need for
revascularization were significantly lower in the enoxaparin
group (22). Because the level of anticoagulant activity
cannot be easily measured in patients given LMWH (e.g.,
activated partial thromboplastin time or activated clotting
time), interventional cardiologists have expressed concern
about the substitution of LMWH for UFH in patients
scheduled for catheterization with possible PCI. However,
Collet et al. (23) have shown in a small nonrandomized
observation study in 293 patients that PCI can be performed
safely with UA/NSTEMI patients who received the usual
dose of enoxaparin. In NICE-1 (National Investigators
Collaborating on Enoxaparin), an observational study, in-
travenous enoxaparin (1.0 mg/kg) was used in 828 patients
undergoing elective PCI without an intravenous GP IIb/
IIIa antagonist (24). The rates of bleeding (1.1% major
bleeding and 6.2% minor bleeding in 30 days) were com-
parable to those observed in historical controls with UFH.
An alternative approach is to use LMWH during the
period of initial stabilization and to withhold the dose on
the morning of the procedure. If an intervention is required
and more than 8 h has elapsed since the last dose of
LMWH, UFH can be used for PCI according to usual
practice patterns. Because the anticoagulant effect of UFH
can be more readily reversed than that of LMWH, UFH is
preferred in patients likely to undergo CABG within 24 h.
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The September 2000 guidelines reflected concern regard-
ing the combined use of LMWH and GP IIb/IIIa antag-
onists. Although the data are not definitive, it now appears
that GP IIb/IIIa antagonists can be used with LMWH. In
the ACUTE II (Anti-thrombotic Combination Using Ti-
rofiban and Enoxaparin II) study (25), UFH and enoxaparin
were compared in patients with UA/NSTEMI who were
given tirofiban. The frequencies of both major and minor
bleeding were similar, and there was a trend to fewer adverse
events in the patients given enoxaparin. A number of other
open-label studies have examined the safety of combining
enoxaparin with abciximab, eptifibatide, or tirofiban in
patients with UA/NSTEMI who are treated with PCI or
conservatively; of combining enoxaparin with abciximab in
patients undergoing elective PCI (26); and of combining
dalteparin with abciximab in patients with UA/NSTEMI
who are treated conservatively and during PCI (27). Al-
though the majority of these studies relied on historical
controls, none suggested that the combination of enoxapa-
rin and a GP IIb/IIIa antagonist was associated with excess
bleeding, whether or not the patient also underwent PCI.
Specific recommendations for the use of heparins in the
revised guidelines are as follows:
Class I
*1. Anticoagulation with subcutaneous LMWH or
intravenous UFH should be added to antiplatelet
therapy with ASA and/or clopidogrel. (Level of
Evidence: A)
Class IIa
*†1. Enoxaparin is preferable to UFH as an anticoagu-
lant in patients with UA/NSTEMI, in the absence
of renal failure and unless CABG is planned
within 24 h. (Level of Evidence: A)
*New indication, not included in the September 2000
guidelines.
†Minor clarification different from full-text version on web
site.
EARLY CONSERVATIVE VS.
EARLY INVASIVE STRATEGIES
The September 2000 guidelines indicated that 2 different
treatment strategies, termed “early conservative” and “early
invasive,” may be used in patients with UA/NSTEMI (1).
In the early conservative strategy, coronary angiography is
reserved for patients with evidence of recurrent ischemia
(angina at rest or with minimal activity or dynamic ST-
segment changes) or a strongly positive stress test despite
vigorous medical therapy. In the early invasive strategy,
patients without clinically obvious contraindications to cor-
onary revascularization are routinely recommended for cor-
onary angiography and angiographically directed revascular-
ization, if possible.
Several trials comparing these 2 strategies were reviewed,
but greatest attention was paid to the then-most-recent
trial, FRISC II (Fragmin and Fast Revascularization during
InStability in Coronary artery disease II) (28). At 1 year, the
mortality rate in the invasive strategy group was 2.2%
compared with 3.9% in the noninvasive strategy group (p 
0.016) (29). However, in FRISC II, the invasive strategy
involved treatment for an average of 6 days in the hospital
with LMWH, ASA, nitrates, and beta-blockers before
coronary angiography, an approach that would be difficult to
adopt in U.S. hospitals.
In the interim, the TACTICS-TIMI 18 trial was re-
ported (7). In this trial, 2,220 patients with UA or
NSTEMI were treated with ASA, heparin, and the GP
IIb/IIIa antagonist tirofiban. They were then randomized to
an early invasive strategy with routine coronary angiography
within 48 h followed by revascularization if the coronary
anatomy was deemed suitable, or to a more conservative
strategy. In the latter, catheterization was performed only if
the patient had recurrent ischemia or a strongly positive
stress test. Death, myocardial (re)infarction, or rehospital-
ization for an acute coronary syndrome at 6 months oc-
curred in 19.4% of patients assigned to the conservative
strategy vs. 15.9% assigned to the invasive strategy (OR
0.78; 95% CI 0.62 to 0.97; p 0.025). Occurrence of death
or MI was also reduced at 6 months (9.5 % vs 7.3%; p less
than 0.05). The beneficial effects on outcome were partic-
ularly evident in medium- and high-risk patients, as defined
by an elevation of troponin T greater than 0.01 ng/ml or of
troponin I greater than 0.1 ng/ml, the presence of ST-
segment deviation, or a TIMI risk score greater than or
equal to 3 (7,30). In the absence of these high-risk features,
outcomes in patients assigned to the 2 strategies were
similar. Rates of major bleeding were similar, and lengths of
hospital stay were reduced in patients assigned to the
invasive strategy. The benefits of the invasive strategy were
achieved at no significant increase in the cost of care over
the 6-month follow-up period.
Thus, both the FRISC II (28,29) and TACTICS-TIMI
18 (7,30) trials, the 2 most recent trials comparing invasive
vs. conservative strategies in patients with UA/NSTEMI,
showed a benefit in patients assigned to the invasive
strategy. In contrast to earlier trials, a large majority of
patients undergoing PCI in these 2 trials received coronary
stents as opposed to balloon angioplasty alone. In
TACTICS-TIMI 18, treatment included the GP IIb/IIIa
antagonist tirofiban, which was administered for an average
of 22 h before coronary angiography. The routine use of the
GP IIb/IIIa antagonist in this trial may have eliminated the
excess risk of early (within 7 days) acute MI in the invasive
arm, an excess risk that was observed in FRISC II and other
trials in which there was no routine “upstream” use of a GP
IIb/IIIa antagonist. Therefore, an invasive strategy is asso-
ciated with a better outcome in UA/NSTEMI patients at
high risk who receive a GP IIb/IIIa antagonist (7). Although
the benefit of GP IIb/IIIa antagonists is well established for
patients with UA/NSTEMI who undergo PCI, the optimum
1371JACC Vol. 40, No. 7, 2002 Braunwald et al.
October 2, 2002:1366–74 ACC/AHA Unstable Angina Guideline Update: Summary Article
time of commencing these drugs—as early as possible after
presentation, i.e. “upstream,” as in TACTICS-TIMI 18, or
just before the PCI—has not been established.
Specific recommendations for the use of an invasive
strategy in the revised guidelines are as follows:
Class I
†1. An early invasive strategy in patients with UA/
NSTEMI without serious comorbidity and who
have any of the following high-risk indicators:
(Level of Evidence: A)
*a) Recurrent angina/ischemia at rest or with low-
level activities despite intensive anti-ischemic
therapy.
*b) Elevated TnT or TnI
*c) New or presumably new ST-segment depres-
sion
d) Recurrent angina/ischemia with CHF symp-
toms, an S3 gallop, pulmonary edema, wors-
ening rales, or new or worsening MR
e) High-risk findings on noninvasive stress test-
ing
f) Depressed LV systolic function (e.g., EF less
than 0.40 on noninvasive study)
g) Hemodynamic instability
h) Sustained ventricular tachycardia
i) PCI within 6 months
j) Prior CABG
2. In the absence of any of these findings, either an
early conservative or an early invasive strategy may
be offered in hospitalized patients without contrain-
dications for revascularization. (Level of Evidence: B)
*New indication, not included in the September 2000
guidelines.
†Minor clarification different from full-text version on web
site.
RISK FACTOR MODIFICATION
The September 2000 guidelines pointed out that despite the
overwhelming evidence for the benefits of beta-hydroxy-
beta-methylglutaryl-coenzyme A (HMG-CoA) reductase
(statin) therapy in patients with elevated low-density li-
poprotein (LDL) cholesterol levels, almost no data existed
about the timing of initiation of therapy in patients with
acute coronary syndromes (1). Indeed, the secondary pre-
vention trials of statins specifically excluded patients with
UA/NSTEMI in the acute phase. Fewer than 300 patients
had been entered into the trials within 4 months of an acute
coronary syndrome.
The Lipid-Coronary Artery Disease (L-CAD) study was
a small trial that randomized 126 patients with an acute
coronary syndrome to early treatment with pravastatin,
alone or in combination with cholestyramine or niacin, or to
usual care. At 24 months, the patients who received early
aggressive treatment had a lower incidence of clinical events
(23%) than the usual-care group (52%; p  0.005) (31). In
the MIRACL (Myocardial Ischemia Reduction with Ag-
gressive Cholesterol Lowering) trial, 3,086 patients were
randomized to treatment with an aggressive lipid-lowering
regimen of atorvastatin 80 mg per day or placebo 24 to 96 h
after an acute coronary syndrome (32). At 16 weeks of
follow-up, the primary end point of death, nonfatal MI,
resuscitated cardiac arrest, or recurrent severe myocardial
ischemia was reduced from 17.4% in the placebo group to
14.8% in the atorvastatin group (p  0.048). There were no
significant differences between the 2 groups in the risk of
the following individual end points: death, nonfatal MI,
cardiac arrest, or worsening heart failure; however, there
were fewer strokes and a lower risk of severe recurrent
ischemia in patients assigned to atorvastatin.
Although the evidence from these 2 trials of a beneficial
effect of predischarge initiation of lipid-lowering therapy is
not yet robust or definitive, observational studies support
this policy. In the Swedish Registry of Cardiac Intensive
Care of almost 20,000 patients, the adjusted relative risk of
mortality was 25% lower in patients in whom statin therapy
was initiated before hospital discharge (33). In addition,
patients in whom lipid-lowering therapy is begun in the
hospital are much more likely to be undergoing such therapy
at a later time. In one demonstration project, the Cardio-
vascular Hospitalization Atherosclerosis Management Pro-
gram (CHAMP), the in-hospital initiation of lipid-
lowering therapy was associated with an increased
percentage of patients treated with statins 1 year later (from
10% to 91%) and with a higher frequency of patients whose
LDL cholesterol was less than 100 mg/dl (from 6% to 58%)
(34). Although additional trials are ongoing, there appear to
be no adverse effects and substantial advantages to the
initiation of lipid-lowering therapy before hospital discharge
(35–37). Such early initiation of therapy has also been
recommended in the third report of the National Choles-
terol Education Program (NCEP III), which also raised the
threshold of high-density lipoprotein cholesterol concentra-
tion that required therapy (38). Similar considerations apply
to the early initiation of statin therapy following PCI. In the
Lescol Intervention Prevention Study (LIPS), 1,669 pa-
tients were randomized to receive 80 mg fluvastatin or
placebo, beginning two days after PCI. After a follow-up of
3.9 years, the statin-treated group had a lower incidence of
clinical events (21.4%) than the placebo group (26.7%), p 
0.01 (39).
In addition to maintaining the original Class I recom-
mendations for LDL cholesterol reduction, specific addi-
tional recommendations for the use of lipid-lowering ther-
apy in UA/NSTEMI in the revised guidelines are as
follows:
Class I
*1. A fibrate or niacin if high-density lipoprotein
cholesterol is less than 40 mg per dl, occurring as
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an isolated finding or in combination with other
lipid abnormalities. (Level of Evidence: B)
Class IIa
*1. HMG-CoA reductase inhibitors and diet for LDL
cholesterol greater than 100 mg per dl begun 24 to
96 h after admission and continued at hospital
discharge. (Level of Evidence: B)
*New indication, not included in the September 2000 guide-
lines.
CONCLUSIONS
These guidelines address the diagnosis and management of
patients with UA and the closely related condition
NSTEMI. These life-threatening disorders are a major
cause of emergency medical care and are responsible for
more than 1.4 million hospitalizations annually in the
United States (40). Nearly 60% of these admissions are
among persons greater than 65 years old, and almost half
occur in women. In 1997, there were 5,315,000 visits to US
emergency departments for the evaluation of chest pain and
related symptoms (41).
Because of the high incidence of UA/NSTEMI and the
seriousness of this condition (approximately 15% rate of
death or [re]infarction at 30 days) (1,20), continued research
in this field is of the greatest importance. It is encouraging
that in the 21 months since the publication of the Septem-
ber 2000 guidelines, a considerable body of additional useful
information about these conditions has emerged. Indeed,
the progress between September 2000 and June 2002 equals
that between 1994, when the first guidelines were published
(42), and September 2000.
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